scispace - formally typeset
K

Kees L. M. C. Franken

Researcher at Leiden University Medical Center

Publications -  154
Citations -  8345

Kees L. M. C. Franken is an academic researcher from Leiden University Medical Center. The author has contributed to research in topics: Antigen & Mycobacterium tuberculosis. The author has an hindex of 51, co-authored 142 publications receiving 7669 citations. Previous affiliations of Kees L. M. C. Franken include Leiden University.

Papers
More filters
Journal ArticleDOI

Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors

TL;DR: The data reveal that PI-9/SPI-6 is an important parameter determining the success of T cell-based immunotherapeutic modalities against cancer, and expression results in the resistance of tumor cells to CTL-mediated killing both in vitro and in vivo.
Journal ArticleDOI

Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis.

TL;DR: Especially strong IFN-gamma responses to latency antigens were observed in latently infected individuals, suggesting that immune responses against these antIGens may contribute to controlling latent M. tuberculosis infection.
Journal ArticleDOI

Purification of his-tagged proteins by immobilized chelate affinity chromatography: the benefits from the use of organic solvent.

TL;DR: A simple and fast, one-step protocol to remove impurities highly efficiently from E. coli proteins, endotoxins, and detergents is described and it is shown that proteins are able to refold correctly after isopropanol treatment.
Journal ArticleDOI

CD8+ CTL Priming by Exact Peptide Epitopes in Incomplete Freund’s Adjuvant Induces a Vanishing CTL Response, whereas Long Peptides Induce Sustained CTL Reactivity

TL;DR: The data clearly show why priming of CTL with minimal peptide epitopes in IFA is suboptimal, and demonstrate that the use of longer versions of these CTL peptides ensures the induction of sustained effector CD8+ T cell reactivity in vivo.